Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic fatty liver (NAFL) and non-
alcoholic steatohepatitis (NASH), represents the hepatic manifestation of obesity and …

Non-alcoholic fatty liver disease (NAFLD) represents a global healthcare challenge,
affecting 1 in 4 adults, and death rates are predicted to rise inexorably. The progressive form …

Drug-induced human hepatotoxicity is difficult to predict using the current in vitro systems. In
this study, long-term 3D organotypic cultures of the human hepatoma HepaRG cell line were …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western
countries. Despite the high prevalence of NAFLD, the underlying biology of the disease …

Compound-induced liver injury leading to fibrosis remains a challenge for the development
of an Adverse Outcome Pathway useful for human risk assessment. Latency to detection and …

Liver diseases such as hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma are one of
the major health challenges in the world and many conditions such as inadequate nutrition …

The introduction of in vitro methodologies in the toxicological risk assessment process
requires a number of prerequisites regarding both the toxicodynamics and the biokinetics of …

Assessment of drug–liver interactions is an integral part of predicting the safety profile of
new drugs. Existing model systems range from in vitro cell culture models to FDA-mandated …

Precision-cut tissue slices have been applied by many researchers because they represent
an organ mini-model that closely resembles the organ from which it is prepared, with all cell …